Entry Point Capital, LLC Dyne Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 7,552 shares of DYN stock, worth $253,822. This represents 0.19% of its overall portfolio holdings.
Number of Shares
7,552Holding current value
$253,822% of portfolio
0.19%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$270 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$264 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$181 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$153 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$143 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.74B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...